All In Biotech

Drug Trial Radar · NCT06345404

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD

A Phase 1, Randomized, Blinded, Placebo-controlled, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of ITK Inhibitor Soquelitinib in Participants With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

82

Actual

Start

Apr 16, 2024

Primary completion

Jan 28, 2026

Study completion Feb 24, 2026

Sponsor

Lead sponsor
Corvus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Apr 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD

Conditions

  • Atopic Dermatitis

Interventions

  • SoquelitinibDrug

    Tablets

  • PlaceboDrug

    Soquelitinib matching placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events, changes in laboratory values, vital signs, and electrocardiogramsTime frame: Up to 30 days after last intervention administration

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Site 5

    Birmingham, Alabama

  • Clinical Site 9

    Tucson, Arizona

  • Clinical Site 3

    North Little Rock, Arkansas

  • Clinical Site 2

    Fremont, California

  • Clinical Site 7

    Palo Alto, California

  • Clinical Site 13

    Pomona, California

  • Clinical Site 10

    Castle Rock, Colorado

  • Clinical Site 6

    Tampa, Florida

  • Clinical Site 11

    Brooklyn, New York

  • Clinical Site 16

    New York, New York

  • Clinical Site 12

    New York, New York

  • Clinical Site 15

    Mayfield Heights, Ohio

  • Clinical Site 1

    Camp Hill, Pennsylvania

  • Clinical Site 8

    Philadelphia, Pennsylvania

  • Clinical Site 4

    Frisco, Texas

  • Clinical Site 14

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.